Oak Ridge, Tennessee, Oct. 25, 2024 (GLOBE NEWSWIRE) — LIS Technologies Inc. (“LIST” or “the Company”), a proprietary developer of advanced laser technology and the only USA-origin and patented laser uranium enrichment company, today announced that Christo Liebenberg, Chief Executive Officer of LIS Technologies Inc. presented at the University of Tennessee’s Nuclear Engineering Colloquium, hosted by the Nuclear Engineering Department.
“We were delighted to welcome our neighbor Mr. Liebenberg to the Nuclear Engineering Department and the University of Tennessee,” said Ashley Nelkin, Academic Specialist & Events of the University of Tennessee Department of Nuclear Engineering. “This Colloquium provides our students and faculty with a rare opportunity to engage with a leading figure in laser isotope separation and gain first-hand insights into this innovative technology.”
Figure 1 – LIS Technologies Inc. Chief Executive Officer Christo Liebenberg will present at the University of Tennessee’s Nuclear Energy Colloquium on October 23, 2024.
The Colloquium included a 45-minute presentation by Mr. Liebenberg, focusing on a comparison of 1st, 2nd, and 3rd generation enrichment technologies, with a particular emphasis on the similarities and differences among various laser enrichment methods. The discussion also covered the fundamentals and requirements of laser enrichment, highlighting 16μm and 5μm MLIS systems. Additionally, key features and benefits of the CRISLA process will be showcased. A 15-minute Q&A session will follow the presentation.
“The University of Tennessee’s Nuclear Engineering Department fosters some of the brightest talent in the country,” said Christo Liebenberg, CEO of LIS Technologies Inc. “It was an honor to lead this seminar and help inspire the next generation of nuclear engineers to push the boundaries of innovation. This event also provides a valuable opportunity to teach about the capabilities of our laser isotope separation technology and better understand its potential. This was an engaging and rewarding seminar.”
About LIS Technologies Inc.
LIS Technologies Inc. (LIST) is a USA based, proprietary developer of a patented advanced laser technology, making use of infrared wavelengths to selectively excite the molecules of desired isotopes to separate them from other isotopes. The Laser Isotope Separation Technology (L.I.S.T) has a huge range of applications, including being the only USA-origin (and patented) laser uranium enrichment company, and several major advantages over traditional methods such as gas diffusion, centrifuges, and prior art laser enrichment. The LIST proprietary laser-based process is more energy-efficient and has the potential to be deployed with highly competitive capital and operational costs. L.I.S.T is optimized for LEU (Low Enriched Uranium) for existing civilian nuclear power plants, High-Assay LEU (HALEU) for the next generation of Small Modular Reactors (SMR) and Microreactors, the production of stable isotopes for medical and scientific research, and applications in quantum computing manufacturing for semiconductor technologies. The Company employs a world class nuclear technical team working alongside leading nuclear entrepreneurs and industry professionals, possessing strong relationships with government and private nuclear industries.
For more information please visit: LaserIsTech.com
For further information, please contact:
Telephone: 800-388-5492
Follow us on Twitter
Follow us on LinkedIn
Forward Looking Statements
This news release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements mean statements related to future events, which may impact our expected future business and financial performance, and often contain words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “will”, “should”, “could”, “would” or “may” and other words of similar meaning. These forward-looking statements are based on information available to us as of the date of this news release and represent management’s current views and assumptions. Forward-looking statements are not guarantees of future performance, events or results and involve known and unknown risks, uncertainties and other factors, which may be beyond our control. For LIS Technologies Inc., particular risks and uncertainties that could cause our actual future results to differ materially from those expressed in our forward-looking statements include but are not limited to the following which are, and will be, exacerbated by any worsening of global business and economic environment: (i) risks related to the development of new or advanced technology, including difficulties with design and testing, cost overruns, development of competitive technology, loss of key individuals and uncertainty of success of patent filing, (ii) our ability to obtain contracts and funding to be able to continue operations and (iii) risks related to uncertainty regarding our ability to commercially deploy a competitive laser enrichment technology, (iv) risks related to the impact of government regulation and policies including by the DOE and the U.S. Nuclear Regulatory Commission; and other risks and uncertainties discussed in this and our other filings with the SEC. Only after successful completion of our Phase 2 Pilot Plant demonstration will LIS Technologies be able to make realistic economic predictions for a Commercial Facility. Readers are cautioned not to place undue reliance on these forward-looking statements, which apply only as of the date of this news release. These factors may not constitute all factors that could cause actual results to differ from those discussed in any forward-looking statement. Accordingly, forward-looking statements should not be relied upon as a predictor of actual results. We do not undertake to update our forward-looking statements to reflect events or circumstances that may arise after the date of this news release, except as required by law.
Attachment
